Sean Senn

Sean Senn is a Director, Life Science Innovation, New Ventures, and Intellectual Property at CommonSpirit Health, a role they began in 2021. In 2010, they Co-Founded Immix Biopharma, Inc., naming the company in honor of their father. In 2022, they began serving as a Board Observer at Zharko Pharma. In 2020, they became General Counsel of fluidIQ, a medical device company founded as a response to the Covid-19 pandemic. In 2018, they founded Accelerator AIX, a firm focused on the translation of early-stage life sciences into a drug or medical device. From 2014 to 2018, they were a Partner and Chair of the patent practice at Archer Norris. Since 2016, they have been an Angel Investor at Pasadena Angels. From 2012 to 2014, they were a Biotechnology and Medical Device Attorney at Nixon Peabody. From 2006 to 2012, they were a Patent Attorney at Davis Wright Tremaine. In 2005, they were an Intellectual Property Attorney at University of California, Irvine, Office of Technology Alliances (UCIOTA).

Sean Senn has a diverse educational background. Sean holds an M.B.A. from UCLA Anderson School of Management, an M.S. in Molecular Biology from Montclair State University, and a B.S. in Biology from UC San Diego. Sean is also a J.D. from the University of San Diego School of Law and is currently a PhD Candidate in Biochemistry at Rutgers University - Newark.